Kyverna Therapeutics & Legend Biotech: Mivocabtagene Autoleucel Clinical Update
This week, the FDA’s ongoing review of CAR-T cell therapies, including Kyverna Therapeutics’ KYV-101 and Legend Biotech’s mivocabtagene autoleucel, marks a critical pivot in autoimmune and oncological medicine. These therapies ... Read More